Coronavirus-related diseases pose a significant challenge to the global health system. Given the diversity of coronaviruses and the unpredictable nature of disease outbreaks, the traditional "one bug, one drug" paradigm struggles to address the growing number of emerging crises. Therefore, there is an urgent need for therapeutic agents with broad-spectrum anti-coronavirus activity. Here, we provide evidence that ATV006, an anti-SARS-CoV-2 nucleoside analog targeting RNA-dependent RNA polymerase (RdRp), has broad antiviral activity against human and animal coronaviruses. Using mouse hepatitis virus (MHV) and human coronavirus NL63 (HCoV-NL63) as a model, we show that ATV006 has potent prophylactic and therapeutic activity against murine coronavirus infection in vivo. Remarkably, ATV006 successfully inhibits viral replication in mice even when administered 96 h after infection. Due to its oral bioavailability and potency against multiple coronaviruses, ATV006 has the potential to become a useful antiviral agent against SARS-CoV-2 and other circulating and emerging coronaviruses in humans and animals.

Objective:To explore the relationship between blood urea nitrogen (BUN) levels and the risk of all-in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated with pneumonia.Methods:This study was a secondary analysis of a multicenter, retrospective cohort study, with data sourced from the DATADRYAD database of five hospitals in Japan (Kameda Hospital, Hyogo Hospital, Awa Hospital, Saiseikai Hospital, and Ichinomiyanishi Hospital). The database included 1 237 cases of AECOPD with pneumonia hospitalized from April 2008 to August 2019, aged≥40 years. After excluding 11 cases with missing BUN level data at admission, a total of 1 226 patients were included in this secondary analysis. BUN level at admission was used as the target independent variable, and all-cause in-hospital mortality during hospitalization was the dependent variable. Risk ratio regression analysis was used to assess the independent correlation between BUN level and the risk of in-hospital mortality due to AECOPD complicated with pneumonia; generalized additive models and smoothing curve fitting methods were applied to explore nonlinear relationships, followed by subgroup analyses to evaluate the consistency of the association across different subgroups and further validate the reliability of the findings.Results:After adjusting for potential confounding factors such as gender and age, BUN levels were positively correlated with the risk of all-cause in-hospital mortality [ OR=1.09(95% CI: 1.01-1.17), P=0.032]. There was a relationship between BUN levels and the risk of all-cause in-hospital mortality, with a turning point at 43.3 mg/dl. The sizes and 95% CI on either side of the turning point were 1.04(0.93-1.16) and 1.08(1.05-1.12), respectively. When BUN>43.3 mg/dl, BUN was correlated with the risk of all-cause in-hospital mortality, with an 8.0% increase in the risk of death for every 1.0 mg/dl increase in BUN ( P<0.05); when BUN<43.3 mg/dl, there was no significant relationship between BUN and the risk of all-cause in-hospital mortality ( P=0.534). Subgroup analysis indicated that in each subgroup of gender, age, source hospital, fever, respiratory, heart rate, crackles in the lungs, change in mental status, corticosteroid therapy, intubation, complete assistance with activities of daily living, medical insurance, and length of hospital stay, the OR value of BUN level had good stability (all OR>1.00) with the risk of all-cause mortality in AECOPD patients with pneumonia. Conclusions:BUN levels are associated with the risk of all-cause in-hospital mortality in patients with AECOPD complicated with pneumonia. When BUN>43.3 mg/dl, BUN levels are positively correlated with the risk of all-cause in-hospital mortality in these patients.

Objective:To explore the relationship between blood urea nitrogen (BUN) levels and the risk of all-in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated with pneumonia.Methods:This study was a secondary analysis of a multicenter, retrospective cohort study, with data sourced from the DATADRYAD database of five hospitals in Japan (Kameda Hospital, Hyogo Hospital, Awa Hospital, Saiseikai Hospital, and Ichinomiyanishi Hospital). The database included 1 237 cases of AECOPD with pneumonia hospitalized from April 2008 to August 2019, aged≥40 years. After excluding 11 cases with missing BUN level data at admission, a total of 1 226 patients were included in this secondary analysis. BUN level at admission was used as the target independent variable, and all-cause in-hospital mortality during hospitalization was the dependent variable. Risk ratio regression analysis was used to assess the independent correlation between BUN level and the risk of in-hospital mortality due to AECOPD complicated with pneumonia; generalized additive models and smoothing curve fitting methods were applied to explore nonlinear relationships, followed by subgroup analyses to evaluate the consistency of the association across different subgroups and further validate the reliability of the findings.Results:After adjusting for potential confounding factors such as gender and age, BUN levels were positively correlated with the risk of all-cause in-hospital mortality [ OR=1.09(95% CI: 1.01-1.17), P=0.032]. There was a relationship between BUN levels and the risk of all-cause in-hospital mortality, with a turning point at 43.3 mg/dl. The sizes and 95% CI on either side of the turning point were 1.04(0.93-1.16) and 1.08(1.05-1.12), respectively. When BUN>43.3 mg/dl, BUN was correlated with the risk of all-cause in-hospital mortality, with an 8.0% increase in the risk of death for every 1.0 mg/dl increase in BUN ( P<0.05); when BUN<43.3 mg/dl, there was no significant relationship between BUN and the risk of all-cause in-hospital mortality ( P=0.534). Subgroup analysis indicated that in each subgroup of gender, age, source hospital, fever, respiratory, heart rate, crackles in the lungs, change in mental status, corticosteroid therapy, intubation, complete assistance with activities of daily living, medical insurance, and length of hospital stay, the OR value of BUN level had good stability (all OR>1.00) with the risk of all-cause mortality in AECOPD patients with pneumonia. Conclusions:BUN levels are associated with the risk of all-cause in-hospital mortality in patients with AECOPD complicated with pneumonia. When BUN>43.3 mg/dl, BUN levels are positively correlated with the risk of all-cause in-hospital mortality in these patients.

Objective To understand the development of healthcare-associated infection(HAI)management organ-izations in China in the past 30 years.Methods Development of HAI management organizations in 12 provinces (municipalities,autonomous regions)in China was surveyed.Results A total of 166 hospitals were surveyed,96 (57.83%)were tertiary hospitals.Among 164 hospitals which had a history of development of HAI management department,46(28.05%)before 1995,63(38.14%)in 1995-2005,and 55(33.54%)in 2005-2015 set up HAI management departments.HAI management professionals per 1 000 beds in 165 hospitals decreased from 4.80 in 1995 to 4.09 in 2015,occupational categories in HAI management departments in 1995 -2015 were significantly different (χ2 =26.22,P <0.01).The constituent ratios of education background and profession of HAI manage-ment professionals in each province in 1995-2015 were significantly different(χ2 =242.91,47.10,respectively,all P <0.01).In 1995 and 2005,70.81%,53.30% of professionals were with college degree or below;in 2015,the percentage of professionals with bachelor’s degree,doctoral degree,and master’s degree were 53.79%,2.45%, and 22.86% respectively.Most professionals were nursing staff,but the percentage decreased from 58.38% in 1995 to 45.96% in 2015.Conclusion Although HAI management organizations have developed for 30 years and made some achievements,there still remain some problems,the proportion of professionals needs to be enhanced,and personnel structure should be optimized.

Objective To understand the development situation of healthcare-associated infection (HAI)manage-ment departments in the rational antimicrobial application and management in hospitals in China.Methods A total of 166 hospitals from 12 provinces,municipalities,autonomous regions,and military hospitals were selected for survey,the participation of HAI management departments in the rational clinical antimicrobial application and man-agement in different years was compared.Results Of 166 hospitals,68(40.96%)in 2005,119(71.69%)in 2010, and 160(96.39%)in 2015 participated in the establishment of management organizations for rational antimicrobial application (χ2 =121.143,P <0.001).The percentage of HAI management departments participating in antimicro-bial management increased from 10.24%(n=17)in 2005 to 22.29%(n=37)in 2010,and 31.33%(n=52)in 2015 (χ2 =22.172,P < 0.001 ).The percentages of HAI management departments participating in formulating cata-logues for antimicrobial varieties and classification,stipulating permission for antimicrobial use,joining antimicrobi-al management teams,monitoring bacterial resistance,managing antimicrobial prophylaxis in clean incision,super-vising clinical antimicrobial use,conducting clinical consultation,and evaluating prescription were 10.87% -30.72% in 2005,25.90%-65.06% in 2010,and 36.14%-95.18% in 2015 (all P <0.01).Intensity of antimicro-bial use (defined daily dose/100 bed-days,DDD/ 100 bed-days)decreased from 69.16 in 2005 to 41.40 in 2015, antimicrobial usage rate decreased from 46.98% in 2005 to 36.90% in 2015,among patients receiving therapeutic antimicrobial use,specimens sending for pathogenic detection increased from 20.58% in 2005 to 49.39% in 2015. Conclusion Departments of HAI management in China play important role in management of rational antimicrobial application.